BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 30413957)

  • 1. Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences.
    Larbi A; Omoumi P; Pasoglou V; Michoux N; Triqueneaux P; Tombal B; Cyteval C; Lecouvet FE
    Eur Radiol; 2019 Aug; 29(8):4503-4513. PubMed ID: 30413957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI.
    Pearce T; Philip S; Brown J; Koh DM; Burn PR
    Br J Radiol; 2012 Aug; 85(1016):1102-6. PubMed ID: 22457319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
    Eiber M; Holzapfel K; Ganter C; Epple K; Metz S; Geinitz H; Kübler H; Gaa J; Rummeny EJ; Beer AJ
    J Magn Reson Imaging; 2011 May; 33(5):1160-70. PubMed ID: 21509875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric whole-body 3.0-T MRI in newly diagnosed intermediate- and high-risk prostate cancer: diagnostic accuracy and interobserver agreement for nodal and metastatic staging.
    Johnston EW; Latifoltojar A; Sidhu HS; Ramachandran N; Sokolska M; Bainbridge A; Moore C; Ahmed HU; Punwani S
    Eur Radiol; 2019 Jun; 29(6):3159-3169. PubMed ID: 30519933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body MRI in oncology: can a single anatomic T2 Dixon sequence replace the combination of T1 and STIR sequences to detect skeletal metastasis and myeloma?
    Chiabai O; Van Nieuwenhove S; Vekemans MC; Tombal B; Peeters F; Wuts J; Triqueneaux P; Omoumi P; Kirchgesner T; Michoux N; Lecouvet FE
    Eur Radiol; 2023 Jan; 33(1):244-257. PubMed ID: 35925384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
    Metser U; Chan R; Veit-Haibach P; Ghai S; Tau N
    AJR Am J Roentgenol; 2019 Feb; 212(2):377-381. PubMed ID: 30332285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images.
    Nakanishi K; Kobayashi M; Nakaguchi K; Kyakuno M; Hashimoto N; Onishi H; Maeda N; Nakata S; Kuwabara M; Murakami T; Nakamura H
    Magn Reson Med Sci; 2007; 6(3):147-55. PubMed ID: 18037795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shortening the acquisition time of whole-body MRI: 3D T1 gradient echo Dixon vs fast spin echo for metastatic screening in prostate cancer.
    Lecouvet FE; Pasoglou V; Van Nieuwenhove S; Van Haver T; de Broqueville Q; Denolin V; Triqueneaux P; Tombal B; Michoux N
    Eur Radiol; 2020 Jun; 30(6):3083-3093. PubMed ID: 32065282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole body MRI in spondyloarthritis (SpA): Preliminary results suggest that DWI outperforms STIR for lesion detection.
    Lecouvet FE; Vander Maren N; Collette L; Michoux N; Triqueneaux P; Stoenoiu M; Houssiau F; Malghem J; Denis ML; Larbi A; Nzeusseu Toukap A
    Eur Radiol; 2018 Oct; 28(10):4163-4173. PubMed ID: 29666994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
    van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
    AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease.
    Pasoglou V; Michoux N; Peeters F; Larbi A; Tombal B; Selleslagh T; Omoumi P; Vande Berg BC; Lecouvet FE
    Radiology; 2015 Apr; 275(1):155-66. PubMed ID: 25513855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
    Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
    Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-body MRI-based multivariate prediction model in the assessment of bone metastasis in prostate cancer.
    Chen R; Yang Q; Chen W; Yang Y; Cheng C; Sun Y; Lu J
    World J Urol; 2021 Aug; 39(8):2937-2943. PubMed ID: 33521882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging.
    Kharuzhyk S; Zhavrid E; Dziuban A; Sukolinskaja E; Kalenik O
    Eur Radiol; 2020 Jul; 30(7):3915-3923. PubMed ID: 32103366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment.
    Barchetti F; Stagnitti A; Megna V; Al Ansari N; Marini A; Musio D; Monti ML; Barchetti G; Tombolini V; Catalano C; Panebianco V
    Eur Rev Med Pharmacol Sci; 2016 Sep; 20(18):3770-3776. PubMed ID: 27735042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of whole-body magnetic resonance diffusion weighted imaging on detection of malignant metastases.
    Li C; Liu ZS; Du XM; He L; Chen J; Wang W; Sun F; Du F; Luo ZG; Xue ZL; Zhao Y; Zhou CW
    Chin Med Sci J; 2009 Jun; 24(2):112-6. PubMed ID: 19618609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence.
    Costelloe CM; Madewell JE; Kundra V; Harrell RK; Bassett RL; Ma J
    Magn Reson Imaging; 2013 Jun; 31(5):669-75. PubMed ID: 23290478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of noncontrast MRI in evaluating breast imaging reporting and data system category 0 lesions on digital mammograms.
    Zhang R; Xu M; Zhou C; Ding X; Lu H; Ge M; Du L; Bu Y
    Quant Imaging Med Surg; 2022 Aug; 12(8):4069-4080. PubMed ID: 35919041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
    Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
    AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.